12/2
03:47 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
01:59 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
04:05 pm
vir
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
11/18
10:50 am
vir
Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]
Low
Report
Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]
11/9
06:11 pm
vir
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile [Yaho
Low
Report
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile [Yaho
11/9
06:07 pm
vir
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
Low
Report
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
11/7
09:00 am
vir
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
Low
Report
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
11/7
01:15 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
12:10 am
vir
Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Medium
Report
Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
11/5
06:00 pm
vir
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/5
04:05 pm
vir
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Low
Report
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
11/3
08:00 am
vir
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
Medium
Report
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
10/22
04:05 pm
vir
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
Medium
Report
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
10/14
12:17 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/9
04:25 pm
vir
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer [Yahoo! Fin
Medium
Report
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer [Yahoo! Fin
10/9
04:05 pm
vir
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
Medium
Report
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
10/7
08:00 am
vir
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
Low
Report
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
9/15
02:58 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.